Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| St. Vincent Hospital, Vienna | OTHER |
Not provided
Not provided
Not provided
The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.
Primarily the influence of the therapeutic treatment on the microRNA concentration in the serum (treatment-response) and the relation between microRNA serum levels and changes of the bone mineral density will be investigated.
These data will help to examine the use of microRNAs as novel diagnostic biomarkers for the diagnosis of osteoporosis and targeted therapeutic treatment of patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 - DMAB | Active Comparator | postmenopausal women without type 2 diabetes mellitus treated with denosumab |
|
| Group 2 - TPTD | Active Comparator | postmenopausal women with type 2 Diabetes mellitus treated with teriparatide |
|
| Group 3 - DMAB | Active Comparator | postmenopausal women with type 2 diabetes mellitus treated with denosumab |
|
| Group 4 - TPTD | Active Comparator | postmenopausal women without type 2 diabetes mellitus treated with teriparatid |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prolia, 60 Mg/mL Subcutaneous Solution | Drug | antiresorptive treatment with Prolia |
|
| Measure | Description | Time Frame |
|---|---|---|
| detection of microRNA concentration in serum | influence of antiresorptive or osteoanabolic Treatment on microRNA levels in postmenopausal women with osteoporosis | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| microRNAs and changes in bone metabolism under treatment | correlation of microRNA with bone turnover markers, fracture risk, BMD | 24 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical University Vienna; St. Vincent Hospital | Vienna | 1060 | Austria |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015663 | Osteoporosis, Postmenopausal |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D010024 | Osteoporosis |
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069448 | Denosumab |
| D019379 | Teriparatide |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Teriparatide | Drug | osteoanabolic treatment with Forsteo |
|
| D008659 |
| Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D004700 | Endocrine System Diseases |
| D007162 |
| Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D010281 | Parathyroid Hormone |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D010455 | Peptides |